Surf Wiki
Save to docs
general/benzamides

From Surf Wiki (app.surf) — the open knowledge base

Momelotinib

Medication

Medication

FieldValue
USANMomelotinib dihydrochloride
JANMomelotinib hydrochloride hydrate
DailyMedIDMomelotinib
pregnancy_AU
ATC_prefix
legal_AU
legal_BR
legal_CA
legal_DE
legal_NZ
legal_UK
legal_US
legal_UN
legal_status
PDB_ligandC87
CH=Ag=Al=As=Au=B=Bi=Br=Ca=Cl=Co=F=Fe=Gd=I=
KLi=Mg=Mn=N=Na=O=P=Pt=S=Sb=Se=Sr=Tc=Zn=charge=

| CYT-387 | CYT-11387 | GS-0387 | Ojjaara | Omjjara

| Drugs.com =

| elimination_half-life =

Momelotinib, sold under the brand name Ojjaara among others, is an anticancer medication used for the treatment of myelofibrosis. It is a Janus kinase inhibitor and it is taken by mouth.

The most common adverse reactions include dizziness, fatigue, bacterial infection, hemorrhage, thrombocytopenia, diarrhea, and nausea.

Momelotinib was approved for medical use in the United States in September 2023, and in the European Union in January 2024.

Medical uses

Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis in adults with anemia.

Pharmacology

Pharmacodynamics

It is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively. The inhibitor is significantly less active towards other kinases, including JAK3 (IC50 = 0.16 μM).

Society and culture

In November 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Omjjara, intended for the treatment of disease-related splenomegaly or symptoms in adults with moderate-to-severe anemia who have primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis. The applicant for this medicinal product is Glaxosmithkline Trading Services Limited. Momelotinib was approved for medical use in the European Union in January 2024.

References

References

  1. (14 January 2025). "Omjjara (GlaxoSmithKline Australia Pty Ltd)".
  2. "OMJJARA momelotinib (as dihydrochloride monohydrate) 100 mg film-coated tablet bottle (442230) {{!}} Therapeutic Goods Administration (TGA)".
  3. (20 December 2024). "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-12-20]".
  4. (8 November 2024). "Ojjaara product information".
  5. (15 September 2023). "Ojjaara- momelotinib tablet". U.S. National Library of Medicine.
  6. (5 August 2011). "Omjjara EPAR".
  7. (26 January 2024). "Omjjara Product information".
  8. (19 September 2023). "FDA Roundup: September 19, 2023".
  9. (15 September 2023). "Novel Drug Approvals for 2023".
  10. "GSK's Omjjara Authorized in EU for Treating Myelofibrosis With Anemia".
  11. (August 2009). "CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients". Leukemia.
  12. (10 November 2023). "Omjjara: Pending EC decision".
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

benzamides 4-morpholinyl-compounds drugs-developed-by-gsk-plc nitriles janus-kinase-inhibitors protein-kinase-inhibitors aminopyrimidines orphan-drugs
Want to explore this topic further?

Ask Mako anything about Momelotinib — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report